Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shenzhen Stock Exchange
  5. Chongqing Zhifei Biological Products Co., Ltd.
  6. News
  7. Summary
    300122   CNE100000V20

CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.

(300122)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Chongqing Zhifei Biological Products : China IMCAS's COVID-19 vaccine obtained emergency use approval in China

03/15/2021 | 08:58am EDT

BEIJING, March 15 (Reuters) - A COVID-19 vaccine developed by the Institute of Microbiology of Chinese Academy of Sciences (IMCAS) has obtained the greenlight for emergency use in China, the institute said on Monday, marking the country's fifth vaccine eligible for some scale of use.

The ZF2001 vaccine, being tested in a late-stage clinical trial aiming to recruit 29,000 participants across China, Uzbekistan, Indonesia, Pakistan and Ecuador, has been approved for use in Uzbekistan earlier this month.

China's vaccine administration law allows emergency use "within certain scope and time limit" of vaccines amid major health crisis. Among the four vaccines China has approved for general public use, three had been approved for small-scale emergency vaccination before gaining clearance for inoculating the wider public.

IMCAS's statement did not specify which specific groups will have access to the vaccine.

The vaccine, which is jointly developed by IMCAS and a unit of Chongqing Zhifei Biological Products, was found to be safe and triggered immune responses in early and mid-stage human tests, according to a paper published last year ahead of peer review.

China, which has been accelerating efforts to vaccinate its population against COVID-19, had administered about 65 million doses as of Sunday.

The country is yet to approve a vaccine developed by foreign companies. (Reporting by Roxanne Liu and Ryan Woo, editing by Louise Heavens)


© Reuters 2021
All news about CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.
08/29Chongqing Zhifei Biological Products Co., Ltd. Reports Earnings Results for t..
CI
08/27CHONGQING ZHIFEI BIOLOGICAL PRODUCTS : China's Zhifei says unit's COVID shot sho..
RE
08/02Chongqing Zhifei Biological Products Co., Ltd. Proposes Final Cash Dividend o..
CI
07/18CHONGQING ZHIFEI BIOLOGICAL PRODUCTS : Zhifei Biological's COVID-19 Vaccine Reta..
MT
06/28Are Chinese COVID-19 shots effective against the Delta variant?
RE
06/11Chongqing Zhifei Biological Products Co., Ltd. Approves 2020 Profit Distribut..
CI
06/09China to study using CanSinoBIO COVID shots as a booster
RE
05/06Shares of China vaccine makers slump on U.S. waiver support
RE
04/20Chongqing Zhifei Biological Products Co., Ltd. Proposes Final Dividend for th..
CI
04/19Chongqing Zhifei Biological Products Co., Ltd. Reports Earnings Results for t..
CI
More news
Financials
Sales 2021 28 304 M 4 378 M 4 378 M
Net income 2021 5 653 M 874 M 874 M
Net cash 2021 2 777 M 429 M 429 M
P/E ratio 2021 40,7x
Yield 2021 0,58%
Capitalization 254 B 39 328 M 39 330 M
EV / Sales 2021 8,89x
EV / Sales 2022 6,66x
Nbr of Employees 3 380
Free-Float 14,7%
Chart CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.
Duration : Period :
Chongqing Zhifei Biological Products Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Last Close Price 158,93 CNY
Average target price 226,30 CNY
Spread / Average Target 42,4%
EPS Revisions
Managers and Directors
Ren Sheng Jiang Chairman & General Manager
Zhen Jing Li Chief Financial Officer & Director
Yu Qin Wu Chairman-Supervisory Board
Bao Kui Liu Independent Director
Gang Deng Independent Director
Sector and Competitors